Business context and reporting period
China Pharma Holdings, Inc. filed this Form 10-K for the fiscal year ended December 31, 2017. The Nevada holding company conducts substantially all operations through its PRC subsidiary, Hainan Helpson, which develops, manufactures and markets prescription pharmaceuticals in China. It reported a portfolio of 19 products and operated GMP-certified production lines.
Key financial results and position
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Revenue | $13.21 million | $15.57 million |
| Gross profit / margin | $2.47 million / 18.7% | $3.22 million / 20.7% |
| Operating loss | $18.68 million | $8.16 million |
| Net loss | $19.28 million | $9.18 million |
| Loss per share, basic and diluted | $0.44 | $0.21 |
| Cash provided by operations | $0.84 million | $2.90 million |
At year-end, cash and cash equivalents were $2.03 million, restricted cash was $0.71 million, current assets were $12.29 million and current liabilities were $9.23 million. Total assets were $59.95 million; total liabilities were $16.88 million; and stockholders’ equity was $43.07 million. The construction loan totaled approximately $9.22 million, including $2.31 million due within one year. The company also owed a director $1.35 million under a related-party loan bearing 1% interest, due by December 31, 2018.
Net cash used in investing activities was $0.14 million and net cash used in financing activities was $1.48 million. Cash declined by $0.64 million during the year. The company stated that its $2.03 million cash balance was held in its PRC subsidiary and was not expected to be available to the parent for dividends or other payments. Current assets exceeded current liabilities by approximately $3.06 million.
Material changes versus the prior year
- Revenue fell 15.2%, primarily attributed to healthcare cost controls and policies limiting drug costs. Anti-infection and respiratory revenue declined 22% to $8.05 million; CNS/cerebral-cardiovascular revenue fell 24% to $2.07 million. “Other” revenue rose 35% to $2.40 million.
- Gross margin declined 2.0 percentage points, with management citing higher raw-material costs, stronger industry and environmental standards, and drug-price controls.
- Operating loss widened substantially, mainly as impairment expense increased to $14.18 million from $3.96 million. The 2017 impairment included $13.64 million related to advances for intangible assets and $0.55 million related to prepaid expenses. Management identified formulas it believed were unlikely to generate positive cash flow following regulatory changes.
- Net loss more than doubled; management attributed the increase primarily to impairment and bad-debt expense. Bad-debt expense rose to $1.39 million from $1.09 million.
- Operating cash flow declined to $0.84 million from $2.90 million. Revenue-related categories remained concentrated: anti-infection/respiratory products accounted for 61% of 2017 sales.
- The PRC subsidiary’s tax rate rose to 25% from 15% after the company did not renew its high-tech enterprise status.
Outlook, risks and unusual items
Management said operating cash flow should fund working-capital needs and anticipated capital expenditures for the next 12 months, while noting that additional financing or spending reductions could be needed if circumstances change. No quantified revenue or earnings guidance was provided. Management said sales increased in the fourth quarter compared with the third quarter and identified sales promotion, provincial drug tenders and exhibitions as priorities.
Generic-drug consistency evaluations and evolving CFDA requirements delayed or suspended pipeline development; management said it suspended pipeline development in 2017 while implementation rules remained uncertain. Approximately $1.1 million remained payable to laboratories and service providers over about four years, subject to completion of contract milestones. The company also faces drug-price and reimbursement pressures, regulatory approval and product-quality risks, competition, distributor and collection risks, PRC currency-conversion and remittance restrictions, and exposure to operating disruption at its single principal manufacturing location.
Receivables warrant close attention: net trade accounts receivable was $2.29 million after an allowance of $18.21 million, and 78.5% of receivables in the reported aging schedule were more than 720 days old. Two customers represented 47.4% and 14.0% of accounts receivable, although no customer exceeded 10% of annual sales. Four suppliers accounted for 19.8%, 17.1%, 15.4% and 11.8% of raw-material purchases.
Management reported a material weakness in internal control over financial reporting, citing insufficient personnel knowledgeable in U.S. GAAP; disclosure controls were deemed ineffective. Management said it was pursuing training and process improvements. The independent auditor gave an unqualified opinion on the financial statements but did not audit or opine on internal-control effectiveness. The filing reported no material pending legal proceedings and no off-balance-sheet arrangements. The company does not anticipate cash dividends in the foreseeable future.
Important facts for investors to verify
- Whether aged receivables are collectible and whether the allowance adequately reflects credit risk, including the large customer balances.
- Whether further impairments or cash losses arise from advances for drug formulas, and the status, cost and commercial prospects of products subject to consistency evaluation.
- Whether the company can sustain positive operating cash flow while meeting construction-loan payments, related-party debt obligations and its $1.1 million milestone-based commitments.
- Whether internal-control remediation addresses the disclosed U.S. GAAP staffing weakness and improves reporting reliability.
- Whether drug pricing, reimbursement, tender and regulatory changes affect sales, gross margins, product approvals or the continued eligibility of products for the market.
- Whether PRC restrictions permit cash generated by Helpson to be transferred to the parent company when needed.